The present disclosure is related generally to biomedical devices and more particularly to a biomedical device for anastomosing engineered tissue and/or organ(s) to in vivo host vasculature.
Despite advances in research and increased awareness of organ donation and transplantation, there continues to be a gap between the need for organs and available organ donations. Currently, more than 100,000 men, women and children are waiting for lifesaving organ transplants. Every ten minutes in the U.S., another person is added to the national transplant waiting list, and 7,000 deaths occur every year in the U.S. because organs are not donated in time. It would be beneficial to develop alternative technologies to enable organ transplantation to take place without waiting for donor organs.
The emerging ability to engineer three-dimensional (3D) vascularized tissues on demand may enable scientific and technological advances in tissue engineering, drug screening, toxicology, 3D tissue culture, organ repair, and organ transplantation. To produce 3D engineered tissue constructs that mimic natural tissues and, ultimately, organs, several key components—cells, extracellular matrix (ECM), and vasculature—may be assembled in complex arrangements. Each of these components plays a vital role: cells are the basic unit of all living systems, ECM provides structural support, and vascular networks provide efficient nutrient and waste transport, temperature regulation, delivery of factors, and long-range signaling routes. Without perfusable vasculature within a few hundred microns of each cell, three-dimensional tissues may quickly develop necrotic regions. Recently, progress has been made in embedding vascular networks in tissue constructs via 3D printing, as described for example in U.S. Pat. No. 10,117,969 to Lewis et al., entitled “Method of Printing a Tissue Construct with Embedded Vasculature,” which is hereby incorporated by reference. In order to successfully employ such vascularized tissue constructs for in vivo applications, it would be advantageous to develop a mechanism to integrate the tissue construct into a host organ or vasculature.
A suturable cuff, a method of integrating a tissue construct with a host organ or vasculature, and a method of making the suturable cuff are described in this disclosure.
The suturable cuff comprises a hollow body having an anastomotic end, an anchoring end, and one or more lumens, where each lumen extends through the hollow body from a proximal opening at the anastomotic end to a distal opening at the anchoring end. The anastomotic end is configured for integration with one or more body vessels, and the anchoring end includes one or more anchoring features for connection with a tissue construct.
The method of integrating a tissue construct with a host organ or vasculature comprises: providing a suturable cuff comprising a hollow body having an anastomotic end, an anchoring end, and one or more lumens, each lumen extending through the hollow body from a proximal opening at the anastomotic end to a distal opening at the anchoring end; anchoring a tissue construct including a vascular channel to the anchoring end of the suturable cuff, the vascular channel being positioned to be in fluid communication with the distal opening(s); inserting the suturable cuff with anchored tissue construct into a body of a patient; anastomosing one or more body vessels to the anastomotic end of the suturable cuff, whereby the one or more body vessels are in fluid communication with the proximal opening(s); and perfusing the suturable cuff and the anchored tissue construct with blood or another bodily fluid from the patient.
A method of making a suturable cuff comprises: providing a mold having a cavity shaped to form an exterior of a hollow body, the cavity comprising an upper cavity portion and a lower cavity portion; filling the lower cavity portion with a precursor material; situating one or more anchoring features at an end of the lower cavity portion at a cavity location shaped to form part of an anchoring end of the hollow body, and situating one or more rods in the lower cavity portion at one or more cavity regions configured to define one or more lumens of the hollow body, wherein the precursor material in the lower cavity portion at least partly surrounds the one or more anchoring features and the one or more rods; placing the upper cavity portion over the lower cavity portion to close the mold; curing the precursor material to form a polymeric body surrounding the one or more rods and part of the one or more anchoring features; and opening the mold and removing the one or more rods, thereby forming a hollow body including the one or more anchoring features, and extracting the hollow body from the mold for use as a suturable cuff.
Referring to
The term “tissue construct” may refer to any engineered tissue or organ that comprises cells and extracellular matrix material, preferably with interpenetrating vasculature.
At the anastomotic end 104, each of the lumens 108 is contained within a tubular or conical projection 114 from the hollow body 102, as shown in
In some examples, the tubular or connection projection(s) 114, as well as other portions or the entirety of the hollow body 102, may comprise a natural or synthetic polymer, such as an elastomer (e.g., silicone, or, more specifically, medical-grade silicone) and/or an extracellular matrix protein (e.g., collagen, fibrin, fibronectin, gelatin, and/or elastin). Advantageously, medical-grade silicone is commercially available in a range of stiffnesses. At a suitable stiffness, the silicone may exhibit a high tear strength, which ensures good suturability. Furthermore, the silicone surface may be modified if desired for hemocompatibility. The lumen 108 extending through the hollow body 102 may have a diameter in a range from about 100 microns to about 10 mm. The diameter may vary along a length of the lumen 108 or may be constant along the length, in which case the lumen 108 may have a cylindrical shape.
The lumen 108 and/or an outer surface of part or all of the hollow body 102 (e.g., the tubular or conical projection(s) 114) may further include a functional coating, which may in some examples may comprise a hydrophilic or zwitterionic polymer, such as polyethylene glycol, polyacrylamide, polyurethane, poly(hydroxyethyl methacrylamide), poly(methacryloyloxylethyl phosphorylcholine), poly(sulfobetaine methacrylate), and/or poly(sulfobetaine acrylamide). It is also contemplated that the functional coating may include an anti-coagulant drug (e.g., heparin). Also or alternatively, the functional coating may include an anti-inflammatory and/or anti-fibrotic agent to reduce inflammation and/or fibrosis in adjacent tissue. The anti-inflammatory and/or anti-fibrotic agent may also or alternatively elute from the hollow body 102. In some examples, the functional coating may be an endothelialized coating comprising an extracellular matrix protein (e.g., collagen or fibronectin) and endothelial cells.
The one or more anchoring features 116 at the anchoring end 106 of the hollow body 102 are designed for engagement with the tissue construct 200. More specifically, the one or more anchoring features 116 are engineered for mechanical and/or chemical attachment (e.g., adhesion) to the tissue construct 200. In some examples, each anchoring feature 116 may comprise a hollow and/or porous structure configured to allow oxygen and nutrient exchange with the tissue construct. Referring to
The anchoring feature(s) 116 may comprise a natural polymer, a synthetic polymer (e.g., polycaprolactone,poly-lactic-co-glycolic acid, or silicone (preferably medical-grade silicone)), and/or a metal or alloy (e.g., aluminum, chromium, cobalt, copper, gold, iron, magnesium, molybdenum, platinum, silver, tantalum, tin, titanium, zinc, zirconium, stainless steel, Ti—Al—V, Co—Cr, and/or Co—Cr—Mo). In some examples, the anchoring feature(s) 116 may be bioresorbable. As shown in
Referring to
The one or more catheter liners 124 may be formed from a polymer such as polytetrafluoroethylene (PTFE), expanded PTFE, polyethylene terephthalate, polyurethane, poly(glycolic acid), polylactic acid, and/or poly lactic-co-glycolic acid. The catheter liner(s) 124 may be endothelialized or chemically modified to provide desired functionality. For example, the one or more catheter liners 124 may include on inner surface(s) thereof a hydrophilic or zwitterionic polymer, such as polyethylene glycol, polyacrylamide, polyurethane, poly(hydroxyethyl methacrylamide), poly(methacryloyloxylethyl phosphorylcholine), poly(sulfobetaine methacrylate), and/or poly(sulfobetaine acrylamide). It is also contemplated that the catheter liner(s) 124 may include an anti-coagulant drug (e.g., heparin). Also or alternatively, the catheter liner(s) 124 may include an anti-inflammatory and/or anti-fibrotic agent to reduce inflammation and/or fibrosis in adjacent tissue. In some examples, the one or more catheter liners 124 may be endothelialized. For example, the one or more catheter liners 124 may include an extracellular matrix protein (e.g., collagen or fibronectin) and endothelial cells.
A method of connecting a tissue construct to a host organ or vasculature is now described in reference to
A tissue construct 200 that includes a vascular channel 202 is anchored to the anchoring end 106 of the suturable cuff 100. During the anchoring, which is described in greater detail below, the vascular channel 202 is positioned to be in fluid communication with the distal opening 112 of the hollow body 102, as illustrated in
Referring now to
After anastomosis, the suturable cuff 100 and the anchored tissue construct 200 may be perfused with blood or another bodily fluid from the patient delivered through the body vessel(s). In experiments with adipose tissue, perfusion and patency of the suturable cuffs and the anchored tissue construct have been demonstrated. The above procedure may be used in various surgical applications such as reconstructive surgery and organ transplants (e.g., kidney transplants).
The anchoring or securing of the tissue construct 200 to the anchoring end 106 of the suturable cuff 100 may take place during or after fabrication of the tissue construct 200. As described above, the anchoring end 106 of the suturable cuff 100 includes one or more anchoring features 116, and thus the anchoring may be understood as partially or fully embedding the one or more anchoring features 116 within the tissue construct 200. In one example, the one or more anchoring features 116 may be inserted into the tissue construct 200 post-fabrication (of the tissue construct 200). Due to the configuration of the anchoring features 116, as illustrated according to several examples in
Alternatively, the anchoring may take place during fabrication of the tissue construct 200. In such an example, the tissue construct 200 may be formed around the anchoring feature(s) 116, such that the one or more anchoring features 116 are partially or fully embedded in the tissue construct 200. Preferably, during fabrication, a vascular channel 202 formed within the tissue construct 200 is positioned to be in fluid communication with the one or more distal openings 112 of the hollow body 102. For example, 3D printing or another fabrication method that allows for both embedding of the anchoring feature(s) 116 into the tissue construct 200 and alignment of the vascular channel(s) 202 with the distal opening(s) 112 may be employed, such that the tissue construct 200 is both anchored to the suturable cuff 100 and is perfusable after implantation into a patient's body.
An exemplary 3D printing process that may be effective for anchoring the anchoring feature(s) 116 of the suturable cuff 100 within the perfusable tissue construct 200 during fabrication is described here in reference to
The tissue or organ precursor material 702 may be compacted (e.g., via centrifugation) in a mold or other container to achieve high cellular density (e.g., up to or greater than about 200 million cells per milliliter), as illustrated in
Also described in this disclosure is a method of making the suturable cuff. In one example, the suturable cuff may be made in a molding process. Alternatively, the suturable cuff may be fabricated by 3D printing. A description of an exemplary molding process is described in reference to
The subject matter of this disclosure may relate to, among others, the following aspects:
A first aspect relates to a suturable cuff for integrating a tissue construct in vivo with a host organ or vasculature, the suturable cuff comprising: a hollow body having an anastomotic end, an anchoring end, and one or more lumens, each lumen extending through the hollow body from a proximal opening at the anastomotic end to a distal opening at the anchoring end, the anastomotic end being configured for integration with one or more body vessels, and the anchoring end including one or more anchoring features for connection with a tissue construct.
A second aspect relates to the suturable cuff of the preceding aspect, wherein the one or more anchoring features are configured for mechanical and/or chemical attachment to the tissue construct.
A third aspect relates to the suturable cuff of any preceding aspect, wherein each of the one or more anchoring features comprises a hollow and/or porous structure configured to allow oxygen and nutrient exchange with the tissue construct.
A fourth aspect relates to the suturable cuff of any preceding aspect, wherein the one or more anchoring features include one or more springs or coils, one or more harpoons, one or more prongs, one or more struts, one or more rings, and/or one or more mesh structures.
A fifth aspect relates to the suturable cuff of any preceding aspect, wherein each of the one or more anchoring features includes two or more rings connected by struts.
A sixth aspect relates to the suturable cuff of any preceding aspect, wherein the one or more anchoring features comprise a natural polymer, a synthetic polymer, and/or a metal or alloy
A seventh aspect relates to the suturable cuff of any preceding aspect, wherein the one or more anchoring features are bioresorbable.
An eighth aspect relates to the suturable cuff of any preceding aspect, wherein the one or more anchoring features are coated with one or more molecules to promote adhesion to the tissue construct, the one or more molecules being selected from the group consisting of: polylactic acid, chitosan, alginate, silanes functionalized with N-hydroxysuccinimide, and aldehydes.
A ninth aspect relates to the suturable cuff of any preceding aspect, further comprising a buffer hydrogel positioned at the anchoring end to promote adhesion to the tissue construct.
A tenth aspect relates to the suturable cuff of any preceding aspect, wherein each anchoring feature has a length in a range from about 500 microns to about 5 mm.
An eleventh aspect relates to the suturable cuff of any preceding aspect, wherein each anchoring feature has a thickness in a range from about 50 microns to about 500 microns.
A twelfth aspect relates to the suturable cuff of any preceding aspect, wherein the hollow body includes two lumens.
A thirteenth aspect relates to the suturable cuff of any preceding aspect, wherein the hollow body includes three lumens.
A fourteenth aspect relates to the suturable cuff of any preceding aspect, wherein the hollow body comprises a natural or synthetic polymer.
A fifteenth aspect relates to the suturable cuff of any preceding aspect, wherein the hollow body and/or the one or more anchoring features comprises an elastomer, such as silicone.
A sixteenth aspect relates to the suturable cuff of any preceding aspect, wherein the hollow body comprises an extracellular matrix protein or material selected from the group consisting of collagen, fibrin, fibronectin, gelatin, and elastin.
A seventeenth aspect relates to the suturable cuff of any preceding aspect, further comprising one or more catheter liners contained within the hollow body, each catheter liner extending from the distal opening to the proximal opening of the hollow body and surrounding one of the lumens.
An eighteenth aspect relates to the suturable cuff of the preceding aspect, wherein the one or more catheter liners comprise polytetrafluoroethylene (PTFE), expanded PTFE, polyethylene terephthalate, polyurethane, poly(glycolic acid), polylactic acid, and/or poly lactic-co-glycolic acid.
A nineteenth aspect relates to the suturable cuff of any preceding aspect, wherein the one or more catheter liners include on inner surface(s) thereof a hydrophilic or zwitterionic polymer.
A twentieth aspect relates to the suturable cuff of any preceding aspect, wherein the one or more catheter liners include on inner surface(s) thereof an anti-coagulant drug.
A twenty-first aspect relates to the suturable cuff of any preceding aspect, wherein the one or more catheter liners include on inner surface(s) thereof an anti-inflammatory and/or anti-fibrotic agent to reduce inflammation and/or fibrosis in adjacent tissue.
A twenty-second aspect relates to the suturable cuff of any preceding aspect, wherein the one or more catheter liners include on inner surface(s) thereof an extracellular matrix protein or material and endothelial cells, the one or more catheter liners being endothelialized.
A twenty-third aspect relates to the suturable cuff of any preceding aspect, wherein, prior to integration with the hollow body, the one or more catheter liners are etched on outer surface(s) thereof to promote adhesion to the hollow body.
A twenty-fourth aspect relates to the suturable cuff of any preceding aspect, wherein the anastomotic end of the hollow body includes proximal tubular or conical projections, and wherein each lumen is contained within one of the proximal tubular or conical projections.
A twenty-fifth aspect relates to the suturable cuff of any preceding aspect, wherein a wall thickness of each tubular or conical projection is in a range from about 100 microns to about 1 mm.
A twenty-sixth aspect relates to the suturable cuff of any preceding aspect, wherein each tubular or conical projection is straight, curved, and/or angled in a predetermined direction.
A twenty-seventh aspect relates to the suturable cuff of any preceding aspect, wherein each tubular or conical projection is flexible.
A twenty-eighth aspect relates to the suturable cuff of any preceding aspect, wherein each lumen has a diameter in a range from about 100 microns to about 10 mm.
A twenty-ninth aspect relates to the suturable cuff of any preceding aspect, wherein the diameter is constant along a length of the respective lumen.
A thirtieth aspect relates to the suturable cuff of any preceding aspect, wherein the diameter varies along a length of the respective lumen.
A thirty-first aspect relates to the suturable cuff of any preceding aspect, wherein the one or more lumens and/or an outer surface of the hollow body includes a functional coating.
A thirty-second aspect relates to the suturable cuff of any preceding aspect, wherein the functional coating comprises a hydrophilic or zwitterionic polymer.
A thirty-third aspect relates to the suturable cuff of any preceding aspect, wherein the functional coating includes an anti-coagulant drug.
A thirty-fourth aspect relates to the suturable cuff of any preceding aspect, wherein the functional coating includes an anti-inflammatory and/or anti-fibrotic agent to reduce inflammation and/or fibrosis in adjacent tissue.
A thirty-fifth aspect relates to the suturable cuff of any preceding aspect, wherein the functional coating comprises an extracellular matrix protein or material and endothelial cells, the functional coating being an endothelialized coating.
A thirty-sixth aspect relates to the suturable cuff of any preceding aspect, having a length from the anchoring end to the anastomotic end in a range from about 2 mm to about 10 mm.
A thirty-seventh aspect relates to a method of integrating a tissue construct with a host organ or vasculature, the method comprising: providing a suturable cuff comprising a hollow body having an anastomotic end, an anchoring end, and one or more lumens, each lumen extending through the hollow body from a proximal opening at the anastomotic end to a distal opening at the anchoring end; anchoring a tissue construct including a vascular channel to the anchoring end of the suturable cuff, the vascular channel being positioned to be in fluid communication with the distal opening(s); inserting the suturable cuff with anchored tissue construct into a body of a patient; anastomosing one or more body vessels to the anastomotic end of the suturable cuff, whereby the one or more body vessels are in fluid communication with the proximal opening(s); and perfusing the suturable cuff and the anchored tissue construct with blood or another bodily fluid from the patient.
A thirty-eighth aspect relates to the method of the preceding aspect, wherein the suturable cuff and the anchored tissue construct are leak-free.
A thirty-ninth aspect relates to the method of the preceding aspect, wherein the anchoring end of the suturable cuff includes one or more anchoring features, and wherein anchoring the tissue construct to the anchoring end of the suturable cuff comprises embedding the one or more anchoring features into the tissue construct.
A fortieth aspect relates to the method of any preceding aspect, wherein embedding the one or more anchoring features within the tissue construct comprises: preparing a tissue or organ precursor material comprising stem cells mixed with an extracellular matrix solution; embedding the one or more anchoring features at the anchoring end of the suturable cuff into the tissue or organ precursor material; moving a nozzle along a print path through the tissue or organ precursor material while a filament comprising a sacrificial ink is extruded through the printing nozzle and deposited along the print path; after deposition of the filament, heating the tissue or organ precursor material to a temperature at which the precursor material stiffens to form the tissue construct and the sacrificial ink liquifies for extraction; and removing the sacrificial ink from the tissue construct to form, within the tissue construct, a vascular channel in fluid communication with the distal opening(s) of the suturable cuff.
A forty-first aspect relates to the method of any preceding aspect, the method further comprising, before embedding the anchoring end of the suturable cuff into the tissue or organ precursor material, compacting the tissue or organ precursor material to increase cellular density.
A forty-second aspect relates to the method of any preceding aspect, further comprising, before moving the nozzle through the tissue or organ precursor material, cooling the tissue or organ precursor material to a temperature at or below 4° C.
A forty-third aspect relates to the method of any preceding aspect, wherein the print path is configured such that each distal opening of the suturable cuff is directly adjacent to a part of the filament.
A forty-fourth aspect relates to the method of any preceding aspect, wherein the temperature to which the tissue or organ precursor material is heated is at least about 37° C.
A forty-fifth aspect relates to the method of any preceding aspect, further comprising seeding the vascular channel with endothelial cells.
A forty-sixth aspect relates to the method of any preceding aspect, wherein embedding the one or more anchoring features into the tissue construct comprises inserting the one or more anchoring features into the tissue construct after fabrication thereof.
A forty-seventh aspect relates to the method of any preceding aspect, wherein anastomosing the body vessel to the anastomotic end comprises suturing the body vessel to the anastomotic end via an end-to-end connection or a side-to-end T connection.
A forty-eighth aspect relates to a method of making a suturable cuff, the method comprising: providing a mold having a cavity shaped to form an exterior of a hollow body, the cavity comprising an upper cavity portion and a lower cavity portion; filling the lower cavity portion with a precursor material; situating one or more anchoring features at an end of the lower cavity portion at a cavity location shaped to form part of an anchoring end of the hollow body; situating one or more rods in the lower cavity portion at one or more cavity regions configured to define one or more lumens of the hollow body, wherein the precursor material in the lower cavity portion at least partly surrounds the one or more anchoring features and the one or more rods; placing the upper cavity portion over the lower cavity portion to close the mold; curing the precursor material to form a polymeric body surrounding the one or more rods and part of the one or more anchoring features; andopening the mold and removing the one or more rods, thereby forming a hollow body comprising the one or more anchoring features, and extracting the hollow body from the mold for use as a suturable cuff.
To clarify the use of and to hereby provide notice to the public, the phrases “at least one of <A>, <B>, . . . and <N>” or “at least one of <A>, <B>, . . . or <N>” or “at least one of <A>, <B>, . . . <N>, or combinations thereof” or “<A>, <B>, . . . and/or <N>” are defined by the Applicant in the broadest sense, superseding any other implied definitions hereinbefore or hereinafter unless expressly asserted by the Applicant to the contrary, to mean one or more elements selected from the group comprising A, B, . . . and N. In other words, the phrases mean any combination of one or more of the elements A, B, . . . or N including any one element alone or the one element in combination with one or more of the other elements which may also include, in combination, additional elements not listed. Unless otherwise indicated or the context suggests otherwise, as used herein, “a” or “an” means “at least one” or “one or more.”
While various embodiments have been described, it will be apparent to those of ordinary skill in the art that many more embodiments and implementations are possible. Accordingly, the embodiments described herein are examples, not the only possible embodiments and implementations.
In addition to the features mentioned in each of the independent aspects enumerated above, some examples may show, alone or in combination, the optional features mentioned in the dependent aspects and/or as disclosed in the description above and shown in the figures.
The present patent document claims the benefit of priority under 35 U.S.C. 119(e) to U.S. Provisional Patent Application No. 63/313,085, which was filed on Feb. 23, 2022, and is hereby incorporated by reference in its entirety.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2023/062916 | 2/21/2023 | WO |
Number | Date | Country | |
---|---|---|---|
63313085 | Feb 2022 | US |